PROCEPT BioRobotics Schedules Q3 2026 Earnings Release for November 4
Event summary
- PROCEPT BioRobotics will report Q3 2026 financial results on November 4, 2026, after market close.
- Management will host a conference call at 4:30 p.m. Eastern Time.
- The company focuses on urology surgical robotics, including the AQUABEAM® and HYDROS® Robotic Systems.
- PROCEPT BioRobotics has approximately 250 peer-reviewed publications supporting its Aquablation therapy.
The big picture
PROCEPT BioRobotics operates in the rapidly evolving surgical robotics sector, where advancements in AI and robotics are transforming urology treatments. The company's focus on BPH (benign prostatic hyperplasia) and prostate cancer positions it in a high-growth segment of the medical device market. With approximately 40 million men in the U.S. affected by BPH, the company's technology has significant market potential. The upcoming earnings release will provide insights into its financial health and strategic direction amid increasing competition and regulatory scrutiny.
What we're watching
- Revenue Growth
- Whether PROCEPT BioRobotics can sustain its growth trajectory in the competitive urology robotics market.
- Clinical Adoption
- The pace at which the company's Aquablation therapy gains broader clinical acceptance.
- R&D Investment
- How the company balances investment in its AI-powered robotic technologies with financial performance.
Related topics